Overview

* Precision BioSciences ( DTIL ) Q3 revenue fell sharply

* Net loss for Q3 widened compared to the same period last year

* Company advances PBGENE-HBV and PBGENE-DMD programs with upcoming clinical milestones

Outlook

* Company anticipates IND filing for PBGENE-DMD by end of 2025

* Precision expects Phase 1 trial for PBGENE-DMD in 1H 2026

* Company projects cash runway into 2H 2027 for clinical milestones

Result Drivers

* PBGENE-DMD ADVANCEMENTS - Co highlighted preclinical data showing potential for PBGENE-DMD to restore dystrophin gene in DMD patients

* COST REDUCTIONS - Co implemented operating efficiencies to reduce expenses and extend cash runway

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $13,000

Revenue

Q3 Net -$21.77

Income mln

Q3 -$20.66

Income mln

from

Operatio

ns

Q3 $20.68

Operatin mln

g

Expenses

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)